RxDoctor Payments Data

Arturo Lopez, MD

Gastroenterology · Ft Lauderdale, FLNPI 1437113834

Payments from drug & device makers

$13,882in general payments, 2019–2025

Across 701 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Bristol Myers Squibb$951
  • Gilead$861
  • QOL Medical, LLC$822
  • plus $4K from 26 others

What the payments were for

  • Food & beverage$13,71999%
  • Education$1631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,882 in reported general payments places this provider in the 75th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$177,595
Medicare patients
396
Services billed
1,864

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SimponiGolimumab14$90,999
LinzessLinaclotide92$66,417
ZenpepLipase/Protease/Amylase12$46,414
CreonLipase/Protease/Amylase12$33,095
Omeprazole442$5,547
Mesalamine15$4,429
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,563
Lubiprostone15$3,561
CholestyramineCholestyramine (With Sugar)26$3,532
Famotidine118$2,159
SynthroidLevothyroxine Sodium24$1,677
Esomeprazole Magnesium43$1,547
Ursodiol22$1,500
Atorvastatin Calcium85$1,329
Pantoprazole Sodium127$1,231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Synthroid$4,167$101,189128 claims
Johnson & JohnsonSimponi$1,106$90,99914 claims
Aimmune Therapeutics, Inc.Zenpep$74$46,41412 claims
Braintree Laboratories, Inc.Sutab$228$3,56322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Ft Lauderdale

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →